Wave Life Sciences (0VS) Ratios
Wave Life Sciences Ratios
DE:0VS's free cash flow for Q3 2026 was $-60.16M. For the 2026 fiscal year, DE:0VS's free cash flow was decreased by $-15.00K and operating cash flow was $-60.14M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.47 | 2.89 | 1.26 | 1.38 | 2.53 |
| Quick Ratio | 6.47 | 2.89 | 1.26 | 1.38 | 2.53 |
| Cash Ratio | 6.33 | 2.72 | 1.07 | 1.24 | 2.35 |
| Solvency Ratio | -1.74 | -0.62 | -0.21 | -0.79 | -0.64 |
| Operating Cash Flow Ratio | -1.97 | -1.36 | -0.10 | -1.79 | -1.39 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 502.55M | $ 177.70M | $ 54.00K | $ -92.94M | $ -11.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.07 | 0.12 | 0.26 | 0.14 |
| Debt-to-Equity Ratio | 0.03 | 0.12 | 0.81 | -0.83 | 0.92 |
| Debt-to-Capital Ratio | 0.03 | 0.11 | 0.45 | -5.03 | 0.48 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.21 | 1.68 | 6.94 | -3.25 | 6.37 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.11 | 0.18 | 0.30 | 0.48 | 0.58 |
| Net Debt to EBITDA | 2.99 | 3.13 | 2.86 | 0.33 | 1.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 79.28% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -478.33% | -89.57% | -60.01% | -4459.30% | -310.07% |
| EBITDA Margin | -457.62% | -81.57% | -51.89% | -4182.13% | -286.06% |
| Operating Profit Margin | -504.09% | -101.94% | -60.01% | -4459.30% | -310.07% |
| Pretax Profit Margin | -478.33% | -89.57% | -51.36% | -4416.06% | -298.92% |
| Net Profit Margin | -478.33% | -89.57% | -50.76% | -4434.72% | -298.42% |
| Continuous Operations Profit Margin | -478.33% | -89.57% | -50.76% | -4434.72% | -298.42% |
| Net Income Per EBT | 100.00% | 100.00% | 98.84% | 100.42% | 99.83% |
| EBT Per EBIT | 94.89% | 87.87% | 85.58% | 99.03% | 96.40% |
| Return on Assets (ROA) | -32.01% | -27.54% | -20.92% | -110.55% | -59.05% |
| Return on Equity (ROE) | -38.84% | -46.30% | -145.12% | 358.88% | -376.16% |
| Return on Capital Employed (ROCE) | -39.63% | -45.76% | -76.82% | -217.35% | -88.94% |
| Return on Invested Capital (ROIC) | -39.03% | -44.36% | -70.58% | -202.49% | -85.81% |
| Return on Tangible Assets | -32.01% | -27.54% | -20.92% | -110.55% | -59.05% |
| Earnings Yield | -7.13% | -5.67% | -10.73% | -29.32% | -75.12% |
| Efficiency Ratios | |||||
| Receivables Turnover | 33.49 | 76.16 | 5.37 | 0.00 | 0.00 |
| Payables Turnover | 0.56 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.15 | 3.87 | 3.17 | 0.08 | 1.01 |
| Asset Turnover | 0.07 | 0.31 | 0.41 | 0.02 | 0.20 |
| Working Capital Turnover Ratio | 0.12 | 0.84 | 2.98 | 0.06 | 0.40 |
| Cash Conversion Cycle | -636.47 | 4.79 | 67.93 | 0.00 | 0.00 |
| Days of Sales Outstanding | 10.90 | 4.79 | 67.93 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 647.37 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 10.90 | 4.79 | 67.93 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.11 | -1.09 | -0.18 | -1.62 | -1.72 |
| Free Cash Flow Per Share | -1.11 | -1.10 | -0.19 | -1.64 | -1.73 |
| Dividend Paid and CapEx Coverage Ratio | -261.13 | -161.01 | -17.43 | -93.89 | -158.92 |
| Capital Expenditure Coverage Ratio | -261.13 | -161.01 | -17.43 | -93.89 | -158.92 |
| Operating Cash Flow Coverage Ratio | -10.55 | -5.94 | -0.60 | -3.40 | -2.97 |
| Operating Cash Flow to Sales Ratio | -4.39 | -1.39 | -0.17 | -35.02 | -2.17 |
| Free Cash Flow Yield | -6.54% | -8.88% | -3.83% | -23.40% | -55.03% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -14.05 | -17.67 | -9.32 | -3.41 | -1.33 |
| Price-to-Sales (P/S) Ratio | 67.10 | 15.79 | 4.73 | 151.27 | 3.97 |
| Price-to-Book (P/B) Ratio | 5.45 | 8.16 | 13.52 | -12.24 | 5.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -15.29 | -11.26 | -26.08 | -4.27 | -1.82 |
| Price-to-Operating Cash Flow Ratio | -15.29 | -11.33 | -27.57 | -4.32 | -1.83 |
| Price-to-Earnings Growth (PEG) Ratio | -0.19 | -0.60 | 0.13 | 0.26 | 0.03 |
| Enterprise Value Multiple | -11.67 | -16.23 | -6.25 | -3.28 | -0.36 |
| Enterprise Value | 2.28B | 1.43B | 367.56M | 501.11M | 42.08M |
| EV to EBITDA | -11.67 | -16.23 | -6.25 | -3.28 | -0.36 |
| EV to Sales | 53.43 | 13.24 | 3.24 | 137.33 | 1.03 |
| EV to Free Cash Flow | -12.18 | -9.44 | -17.89 | -3.88 | -0.47 |
| EV to Operating Cash Flow | -12.18 | -9.49 | -18.92 | -3.92 | -0.47 |
| Tangible Book Value Per Share | 3.12 | 1.52 | 0.37 | -0.57 | 0.63 |
| Shareholders’ Equity Per Share | 3.12 | 1.52 | 0.37 | -0.57 | 0.63 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.01 | -0.00 | 0.00 |
| Revenue Per Share | 0.25 | 0.78 | 1.07 | 0.05 | 0.79 |
| Net Income Per Share | -1.21 | -0.70 | -0.54 | -2.05 | -2.36 |
| Tax Burden | 1.00 | 1.00 | 0.99 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.86 | 0.99 | 0.96 |
| Research & Development to Revenue | 4.28 | 1.47 | 1.15 | 31.75 | 2.98 |
| SG&A to Revenue | 1.76 | 0.54 | 0.45 | 13.84 | 1.13 |
| Stock-Based Compensation to Revenue | 0.00 | 0.12 | 0.09 | 4.71 | 0.40 |
| Income Quality | 0.92 | 1.56 | 0.34 | 0.79 | 0.73 |
Currency in USD